LL-37 (Cathelicidin)
Peptide therapy: benefits, side effects, cost and protocols
Also known as Cathelicidin LL-37
A human antimicrobial peptide that plays a key role in innate immunity. Provides direct antimicrobial defense and modulates immune cell signaling.
Sources: FDA / PubMed / ClinicalTrials.gov View
Spec sheet
- Typical cost
- $150 to $350/mo
- FDA status
- Research (RFK 2026 reclassification)
- Evidence
- Moderate: well-characterized mechanism
Who it's for
Who LL-37 (Cathelicidin) is usually considered for
- Immune support
- Antimicrobial defense
- Infection management
Compound
LL-37 (Cathelicidin) compound data
- Formula
- C205H340N60O53
- Mol. weight
- 4493 g/mol
- PubChem CID
- 16198951 ↗
- IUPAC
- (4S)-5-[[(1S)-5-amino-1-[[(1S,2S)-1-[[2-[[(1S)-5-amino-1-[[(1S)-1-[[(1S)-2-[[(1S)-5-amino-1-[[(1S)-1-[[(1S,2S)-1-[[(1S)-1-[[(1S)-4-amino-1-[[(1S)-1-[[(1S,2S)-1-[[(1S)-5-amino-1-[[(1S)-2-[[(1S)-2-[[(1S)-1-[[(1S)-1-[[(1S)-3-amino-1-[[(1S)-1-[[(1S)-1-[(2S)-2-[[(1S)-1-[[(1S,2R)-1-[[(1S)-3-carboxy-1-[[(1S)-1-carboxy-2-hydroxy-ethyl]carbamoyl]propyl]carbamoyl]-2-hydroxy-propyl]carbamoyl]-4-guanidino-butyl]carbamoyl]pyrrolidine-1-carbonyl]-2-methyl-propyl]carbamoyl]-3-methyl-butyl]carbamoyl]-3-oxo-propyl]carbamoyl]-4-guanidino-butyl]carbamoyl]-3-methyl-butyl]amino]-1-benzyl-2-oxo-ethyl]amino]-1-(carboxymethyl)-2-oxo-ethyl]carbamoyl]pentyl]carbamoyl]-2-methyl-butyl]carbamoyl]-4-guanidino-butyl]carbamoyl]-4-oxo-butyl]carbamoyl]-2-methyl-propyl]carbamoyl]-2-methyl-butyl]carbamoyl]-4-guanidino-butyl]carbamoyl]pentyl]amino]-1-benzyl-2-oxo-ethyl]carbamoyl]-3-carboxy-propyl]carbamoyl]pentyl]amino]-2-oxo-ethyl]carbamoyl]-2-methyl-butyl]carbamoyl]pentyl]amino]-4-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-amino-4-methyl-pentanoyl]amino]-4-methyl-pentanoyl]amino]acetyl]amino]-3-carboxy-propanoyl]amino]-3-phenyl-propanoyl]amino]-3-phenyl-propanoyl]amino]-5-guanidino-pentanoyl]amino]hexanoyl]amino]-3-hydroxy-propanoyl]amino]hexanoyl]amino]-5-oxo-pentanoic acid
News
LL-37 (Cathelicidin) in the news
Human cathelicidin peptide LL-37 compacts nucleic acids and alters neutrophil extracellular trap structure - Nature
Nature / 6 months ago
Engineered Hybrid Peptide Neutralizes Bacterial Endotoxin and Combats Poultry Pathogens - Bioengineer.org
Bioengineer.org / 4 days ago
The Human Cathelicidin Antimicrobial Peptide LL-37 and Mimics are Potential Anticancer Drugs - Frontiers
Frontiers / 41 months ago
The structure of the antimicrobial human cathelicidin LL-37 shows oligomerization and channel formation in the presence of membrane mimics | Scientific Reports - Nature
Nature / 74 months ago
Membrane Core-Specific Antimicrobial Action of Cathelicidin LL-37 Peptide Switches Between Pore and Nanofibre Formation | Scientific Reports - Nature
Nature / 121 months ago
News aggregated via Google News. Inclusion does not imply endorsement.
Related
Other Immune & Autoimmune peptides
Full peptide index →Considering LL-37 (Cathelicidin)?
The 2-minute quiz matches you with licensed providers who offer it. A clinician decides if it fits.